Though yet to be finalised, the initial recommendation would mean the injectable PrEP would not be covered on the NHS.

Biotechs and investors are increasingly altering their strategies amid changes in the development and commercial landscape.

EMC181 aims to address DMD by activating utrophin in muscle using CRISPR-GNDM. Credit: MY STOCKERS / Shutterstock.com. Exegenesis Bio and Modalis Therapeutics have entered a research partnership and ...

ABEC is to open a new manufacturing facility in Wilson, North Carolina, US, expanding its network for biopharmaceutical process equipment.

Encoded Therapeutics has raised $275m in a Series F financing round to advance development of its disease-modifying therapy (DMT) for Dravet syndrome, with an eye also on initiati ...

Cholesterol-lowering drugs, pulmonary hypertension, and drug adherence all feature in this wrap-up of the two important scientific congresses. Credit: GlobalData. It’s conference season again. In this ...

Thoracic oncologists previously touted the potential of Bayer's Hyrnuo in HER2-mutant NSCLC in both the first- and second-line settings.

The HHS appoints these leadership positions as it looks to “reform” the FDA, which has recently faced a high turnover in leadership.

Porustobart is a second-generation, Fc-enhanced CTLA-4 antibody developed by Harbour BioMed. Credit: T. Schneider / Shutterstock.com. Harbour BioMed’s partner Solstice Oncology has raised $225m in ...

TwoStep’s approach uses a PIP that is designed to bind five tumour-associated integrins present in various solid tumours. Credit: angellodeco / Shutterstock.com. TwoStep Therapeutics has raised $62.5m ...